2023 Correspondence
- Letter to White House Initiative on Women’s Health Research
December 2023 | The CAMT Steering Committee sent a letter to White House Initiative on Women’s Health Research Chair Dr. Carolyn Mazure requesting that the White House prioritize the inclusion of pregnant and lactating populations in clinical trials as part of its recommendations - Letter to House and Senate Labor-HHS Appropriations Subcommittee Leadership
November 2023 | Members of the CAMT sent a letter to leaders of the House and Senate Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittees requesting $200,000 in final fiscal year 2024 legislation for the Advisory Committee to implement the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations - Letter to FDA
October 2023 | Members of CAMT sent a letter to FDA urging it to harmonize its regulations and guidance governing the inclusion of pregnant women in clinical research with the Common Rule - Dear Colleague Letter to FDA
October 2023 | Members of Congress sent a letter to FDA urging the agency to harmonize its regulations and guidance with the Common Rule
2021 Correspondence
- Letter to Cures 2.0 Sponsors
December 2021 | Members of CAMT joined a letter to congressional supporters of the Cures 2.0 Act urging them to include provisions to advance maternal therapeutics in the legislative package - Letter to Secretary Becerra
June 2021 | CAMT sent a letter to U.S. Department of Health and Human Services (HHS) Secretary Becerra outlining opportunities for HHS to promote the inclusion of pregnant and lactating populations in clinical trials - Letter to President Biden and Vice President Harris
March 2021 | CAMT sent a letter to President Biden and Vice President Harris highlighting policy changes necessary to promote the inclusion of pregnant and lactating populations in clinical trials - Letter to CDC’s Advisory Committee on Immunization Practices
March 2021 | CAMT sent a letter to CDC’s Advisory Committee on Immunization Practices regarding accessing to Janssen Biotech Inc. COVID-19 vaccine for pregnant and lactating populations - Letter to FDA’s Vaccines and Related Biological Products Advisory Committee
February 2021 | CAMT sent a letter to FDA’s Vaccines and Related Biological Products Advisory Committee on access to the Janssen Biotech Inc. COVID-19 vaccine for pregnant and lactating populations
2020 Correspondence
- Letter to FDA’s Office of Women’s Health
September 2020 | 22 CAMT members, in response to a Request for Comments, urged FDA’s Office of Women’s Health to include promoting the inclusion of pregnant women and lactating women in clinical trials as a strategic priority - Public Comments
June 2020 | CAMT provided public comments during a meeting of PRGLAC to discuss the implementation of its September 2018 report to HHS Secretary Azar - Letter to NIH and FDA
March 2020 | CAMT wrote a letter to NIH and FDA leadership calling for the inclusion of pregnant and lactating women in clinical trials related to COVID-19
2019 Correspondence
- Public Comments
August 2019 | CAMT provided public comments during a meeting of PRGLAC to discuss the implementation of its September 2018 report to HHS Secretary Azar
2018 Correspondence
- Letter to Secretary Azar
October 2018 | CAMT wrote a letter to Secretary Azar urging him to implement the recommendations of PRGLAC as soon as possible
2017 Correspondence
- Letter to Secretary Price
June 2017 | Members of the CAMT Steering Committee wrote to Secretary Price to ask that he move quickly and approve a slate for members of PRGLAC